Related Experiment Video
Updated: May 31, 2026
Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads
Published on: July 21, 2017
Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist
Yasmine Mohseni1,2, Aria Vazirnia2, Ardalan Minokadeh3
1Department of Medical Education, University of Miami Miller School of Medicine, Miami, Florida.
Background:
Lipedema is a chronic disorder characterized by disproportionate accumulation of subcutaneous fat, most commonly affecting the extremities, and is associated with pain, inflammation, and fibrosis. Effective medical therapies are lacking, and liposuction remains the primary treatment. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate metabolic and anti-inflammatory effects, but their role in lipedema remains unclear.
Objective:
To evaluate the potential role of GLP-1-based therapies in the management of lipedema.
Methods:
A literature search of peer-reviewed articles published through March 2026 was conducted using PubMed. Search terms included "lipedema and GLP-1" and related combinations of GLP-1 RAs, tirzepatide, inflammation, and insulin resistance. Relevant studies in lipedema, obesity, and fibroinflammatory conditions were included.
Results:
Thirteen publications were identified. Two specifically evaluated GLP-1 RAs in lipedema, with only 1 providing direct patient evidence. A small uncontrolled case series of 5 patients treated with exenatide reported improvements in pain and limb volume. Translational evidence suggests that GLP-1 RAs, particularly tirzepatide, may influence inflammatory and fibrotic pathways relevant to lipedema.
Conclusion:
To date, GLP-1 RAs have not been proven to have direct effects on lipedema progression. However, given their known role in weight reduction and metabolic improvement, they may provide benefit as adjunctive therapies.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:23Dipeptidyl Peptidase 4 Inhibitors